HIGHBuilt-inPipeline
EDIT-401
“10-K Item 1A: 'We are dependent on the success of our lead product candidate, EDIT-401 ... our business is significantly dependent upon this one product candidate'”
EDIT · Concentration risk · 10-K extracted
Editas Medicine (EDIT) concentration risks
Updated
The most significant concentration Editas Medicine discloses is EDIT-401, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Editas Medicine’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Editas Medicine's disclosed concentration risk is a single-asset dependency: the company states it is dependent on the success of its lead product candidate, EDIT-401, and that its business is significantly dependent upon this one product candidate. This is a structural rather than counterparty-driven exposure — it isn't a supplier or customer relationship that could be renegotiated or replaced, but the company's entire near-term value proposition resting on one clinical program. With no other concentration exposures disclosed, there is nothing to offset or diversify this risk within the filing; a clinical setback for EDIT-401 would directly and fully affect the company, since there is no second program, customer base, or geographic spread mentioned to cushion it. The high disclosed share underscores that this is not a minor or hedged risk. For a clinical-stage gene-editing company, this single-candidate dependency is a common shape of risk, but the lack of any additional disclosed exposures also means the filing offers no additional texture — the entire concentration story for Editas, as filed, is this one program.
For the engine’s reasoning on EDIT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| EDIT● | Editas Medicine, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.